Potassium channel blockers or derivatives thereof for preventing, alleviating, and/or treating morbidity and mortality induced by pathogens or other inducers of immune exhaustion and/or excess immune activati

A method of preventing, alleviating, or treating a disease, disorder, or condition in a subject in need thereof,

• wherein the method comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising at least one potassium channel blocker or an analog, a racemate, a tautomer, an isomer, an enantiomer, a diastereomer, a prodrug, a pharmaceutically acceptable salt, or a derivative thereof;
• wherein the disease, disorder, or condition is:
• (a) death caused by an exposure to an infectious pathogen capable of causing a severe or critical disruption in a normal tissue function when the method is a method of preventing a condition in the subject;
• (b) death preceded by a hyper-activation of the immune system, hypercytokinemia, cytokine storm, cytokine release syndrome, immune system exhaustion, or any combination thereof when the method is a method of preventing a condition in the subject;
• (c) a tissue damage, tissue dysfunction, or any combination caused by a hyper-activation of the immune system, hypercytokinemia, cytokine storm, cytokine release syndrome, immune system exhaustion, or any combination thereof caused by a graft-versus-host disease, exposure to radiation, exposure to an infectious pathogen, sepsis, or any combination thereof, wherein the infectious pathogen is capable of causing a severe or critical disruption in a normal tissue function;
• (d) a mitochondrial damage, mitochondrial dysfunction, lysosomal damage, lysosomal dysfunction, or any combination thereof caused by an exposure to an insult capable of compromising an immune system function, infectious pathogen capable of causing a severe or critical disruption in a normal tissue function, or any combination thereof;
• (e) an axonal damage or axonal dysfunction caused by an exposure to an insult capable of compromising an immune system function, infectious pathogen capable of causing a severe or critical disruption in a normal tissue function, or any combination thereof;
• (f) at least one gait abnormality caused by an exposure to an insult capable of compromising an immune system function, infectious pathogen capable of causing a severe or critical disruption in a normal tissue function, or any combination thereof;
• (g) a hyper-activation of the immune system, hypercytokinemia, cytokine storm, cytokine release syndrome, immune system exhaustion, or any combination thereof caused by a graft-versus-host disease or an exposure to an infectious pathogen capable of causing a severe or critical disruption in a normal tissue function;
• (h) the morbidity or mortality caused by a graft-versus-host disease;
• (i) the morbidity or mortality caused by a sepsis, wherein the sepsis is caused by exposure to an infectious pathogen;
• or
• (j) any combination thereof.